Results of Operations and Financial Condition. On August 14, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…

Results of Operations and Financial Condition. On May 15, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Other Events. On May 13, 2026, the Company announced, by way of the press release attached hereto as Exhibit 99.1, the pricing of the offering described above and plans to create an independent business entity composed of the AI platform, withZeta.ai, and related technologies and personnel under the leadership of CEO Mr. Panna Sharma. The Company intends to separate its public facing AI technology assets into an independent business entity in order to access dedicated funding sources and pote…

Entry into a Material Definitive Agreement. On May 12, 2026, Lantern Pharma Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors, pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering (i) 1,454,175 shares (the “Common Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, at an offering price of $2.06 per share, and (ii) pre-funded warran…

Unregistered Sale of Equity Securities. The applicable information set forth in

Results of Operations and Financial Condition. On March 30, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities…

Results of Operations and Financial Condition. On November 13, 2025, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act…

Results of Operations and Financial Condition. On August 13, 2025, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…

Director — Lee T. Schalop, M.D.: Dr. Lee T. Schalop was appointed to the Board of Directors.

Entry Into a Material Definitive Agreement . On July 3, 2025, Lantern Pharma Inc., a Delaware corporation (the “Company”), entered into an ATM Sales Agreement (the “Sales Agreement”) with ThinkEquity LLC (the “Agent”), pursuant to which the Company may offer and sell up to $15,530,000 maximum aggregate offering price of shares (the “Placement Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”) from time to time through the Agent, acting as sales agent or pri…

Results of Operations and Financial Condition. On May 15, 2025, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Results of Operations and Financial Condition. On March 27, 2025, Lantern Pharma Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exc…

Chief Scientific Officer — Kishor G. Bhatia: The employment agreement for the Chief Scientific Officer was amended to extend the term, adjust working hours, and proportionately adjust the annual base salary.

Results of Operations and Financial Condition. On November 7, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act…

Results of Operations and Financial Condition. On August 8, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Results of Operations and Financial Condition. On May 9, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Results of Operations and Financial Condition. On March 18, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities…

Compensation adjustments for existing officers.

Entry into a Material Definitive Agreement. On November 21, 2023, Lantern Pharma Inc. (“Company”) entered into separate Securities Purchase Agreements with Bios Fund I QP, LP and Bios Fund I, LP (the “Bios Entities”) pursuant to which the Company agreed to purchase from the Bios Entities a total of 145,348 shares (the “Shares”) of Company common stock, at a purchase price of $3.44 per share, for a total purchase price of $499,997.12. The agreements contain customary representations, warrantie…

Results of Operations and Financial Condition. On November 8, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act…

Results of Operations and Financial Condition. On August 9, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Results of Operations and Financial Condition. On May 9, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31 , 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Results of Operations and Financial Condition. On March 20, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31 , 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securitie…

Kishor G. Bhatia: Compensation increase for Chief Scientific Officer.

Results of Operations and Financial Condition. On November 7, 2022, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30 , 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act…